Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - April 2014


2nd Annual Biosimilars & Biobetters Congress 2014

03 Apr 2014 - 04 Apr 2014



Bookmark and Share


Over 400 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions

25 presentations, case studies and panel discussions focused on the key issues in follow-on biologics development and commercialisation

2 interactive streams:

  • Market Opportunities and Commercial Challenges
  • Developing Biosimilars and Biobetters

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

Co-located with the 7th Annual Proteins & Antibodies Congress & the Peptides Congress Oxford Global are proud to present the Biosimilars & Biobetters Congress, taking place on 3-4 April 2014 at Novotel London West, UK.

The follow on biologics industry is forecast to reach $8.8 billion by 2017. Our conference programme focuses on the challenges, innovations and technologies that promise to put this sector at the forefront of the pharmaceutical industry.

The 2nd Annual Biosimilars and Biobetters Congress features two streams:

Market Opportunities & Commercial Challenges: In Stream 1, the meeting will address the most pressing challenges in gaining access to emerging markets and branding biosimilars through a series of cutting-edge conference presentations. Our boisimilars experts will also debate how to overcome regulatory challenges, outsource manufacturing and develop pricing strategies

Developing Biosimilars & Biobetters: Learn more about current developments in clinical trials, including pharmacovigilence and patient safety. Do not miss out on the chance to discover innovative solutions for achieving quality by design, demonstrating biosimilarity and addressing potency as well as the latest insights into the regulatory requirements and trial design.

The Biosimilars & Biobetters Congress is part of the highly successful Oxford Global Proteins Series.

Further information
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
“Amazing Protein Diversity” Discovered in Maize
The genome of the corn plant – or maize, as it’s called almost everywhere except the US – “is a lot more exciting” than scientists have previously believed. So says the lead scientist in a new effort to analyze and annotate the depth of the plant’s genetic resources.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Nanoprobe Enables Measurement of Protein Dynamics in Living Cells
Mass. General and Harvard researchers use device to measure how anesthetic affects levels of Alzheimer's-associated proteins.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!